A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Protocol No

CVC-CYTOKINETICS-CY6033

Staff Member

Abhinav Sharma

Phase

III

Summary

This project is being done to compare the effects of an investigational drug for nHCM, aficamten, and placebo on health status and exercise capacity in participants with nHCM. The safety and tolerability of aficamten at different, increasing dose levels will also be studied.

Objective

Aficamten v Placebo in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Study Sites

Froedtert Hospital

Status

OPEN TO ACCRUAL